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Abstract Over the last decade, the noncoding part of the
genome has been shown to harbour thousands of cis-regula-
tory elements, such as enhancers, that activate well-defined
gene expression programs. Driven by the development of nu-
merous techniques, many of these elements are now identified
in multiple tissues and cell types, and their characteristics as
well as importance in development and disease are becoming
increasingly clear. Here, we provide an overview of the in-
sights that were gained from the analysis of noncoding gene
regulatory elements in the brain and describe their potential
contribution to cell type specialization, brain function and
neurodegenerative disease.
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Introduction
Cell state specification is determined by the tight control of
gene expression programs that arise as a result of pre-
programmed developmental cascades as well as environmen-
tal stimuli [1, 2]. Transcriptional regulation is a dynamic pro-
cess and is guided by transcription factors that occupy cis-
regulatory elements (CREs) in noncoding parts of the ge-
nome. CREs are short stretches of DNA that contain recogni-
tion motifs onto which transcription factors can dock [3].
These in turn recruit cofactors that modify the local chromatin
environment and that influence the assembly of a functional
transcriptional apparatus at the core promoter of genes.
Our understanding of the basic principles of gene regula-
tion and the role that transcription factors play in this process
have increased substantially over the last 10 years [4]. Close to
1400 transcription factors have been identified [5] and recent
advances in large-scale sequencing techniques are further
expanding our insights of transcriptional regulation by
allowing the identification of hundreds of thousands of
CREs as well as the networks in which they operate [6].
Small sets of master regulators have emerged as central to
the coordination of these transcriptional networks during de-
velopment [4, 7]. Accordingly, overexpression of such factors
can initiate reprogramming of fully differentiated cells to-
wards a different developmental path [8]. Thus, while study-
ing transcription factors and their regulatory networks has
provided critical insight into the processes of cell state speci-
fication, it has also allowed us to control these states.
Numerous diseases, including most cancers, are caused by
aberrant transcriptional regulation which is often the result of
mutations in transcription factors or their associated cofactors
[4]. Interestingly, a number of diseases have also been linked
to mutations within CREs [9–11]. In addition, most single
nucleotide polymorphisms (SNPs), associated with a variety
of disorders, have been identified in noncoding DNA [12].
Therefore, efforts to understand the genetic and epigenetic
basis of pathology have significantly shifted focus from cod-
ing sequences (i.e. genes) towards noncoding regulatory ele-
ments. This is especially the case for complex diseases such as
neuropsychiatric and neurodegenerative disorders, in which
much of the underlying heritability has remained elusive [13].
In the current review, we focus on gene expression control
in the human brain. We summarise how large-scale identifica-
tion of cis-regulatory DNA is starting to broaden our
This article is part of the Topical Collection on Genetics
* Menno P. Creyghton
m.creyghton@hubrecht.eu
1 Hubrecht Institute-KNAW and University Medical Center Utrecht,
Uppsalalaan 8, 3584CT Utrecht, The Netherlands
Curr Neurol Neurosci Rep (2016) 16: 94
DOI 10.1007/s11910-016-0689-7
understanding of transcriptional programs in the brain and
how this knowledge can be used to uncover gene regulatory
alterations that contribute to complex brain diseases.
Unravelling Transcriptional Programs in the Brain
For decades, scientists have been attempting to unravel the
transcriptional programs that give rise to the wide variety of
neuronal cell types that collectively make up the central ner-
vous system. Several transcription factors were shown to play
key roles in neurogenesis and neuronal diversification (for an
extensive review see [14]). For instance, the expression of
Dlx1 (distal-less homeobox 1) and Dlx2 counteracts the ex-
pression of Olig1 (oligodendrocyte transcription factor 1) and
Olig2 to promote interneuron fate over oligodendrocyte spec-
ification and vice versa [15, 16]. Furthermore, upregulation of
the transcription factor Pax6 (paired box 6) induces
neurogenesis through induction of Ngn2 (neurogenin 2)
[17]. Surprisingly, overexpression of Pax6 could also induce
neurogenesis in post-natal astrocytes in vitro, representing one
of the earliest examples of lineage conversion directed by a
single transcription factor [18]. Ngn2 as well as Ascl1
(achaete-scute homolog 1), another key factor in
neurogenesis, was also shown to be able to drive neuronal cell
fate specification in post-natal astrocytes suggesting that dif-
ferentiation boundaries could be overcome using specific tran-
scription factors [19]. Following these discoveries, select
combinations of transcription factors were identified that,
when overexpressed, were able to induce major cell state
changes [8]. This included the direct conversion of fibroblasts
into neuronal cell types [20], which has now been achieved
through overexpression of different combinations of neuronal
transcription factors, typically using Ascl1 as a cornerstone
factor (reviewed in [21]). These data demonstrate that tran-
scription factors play a central role in determining cell state
specification in the nervous system as well as in controlling
the plasticity of these states.
Following the emergence of genome-scale tran-
scriptome analyses, spatio-temporal gene expression pro-
grams in the brain are now rapidly being elucidated.
Large consortia, including the Allen Institute for Brain
Science and BrainSpan, have collected gene expression
data in murine and human tissues at different develop-
mental stages as well as in brain tissue from humans suf-
fering from neurological disorders [22, 23]. Furthermore,
co-expression analysis of these types of data has revealed
a hierarchical structure of networks in which certain tran-
scription factors present as central (hub) genes that mod-
ulate the expression of other genes [22, 24, 25]. For in-
stance, TBR1 (T-brain 1) and EMX2 (empty spiracles ho-
meobox 2) have emerged as hub regulators in the adult
human brain [25] and are well-known cortical transcrip-
tion factors involved in state specification of cortical
progenitors and adult neurons [26]. While these analyses
are starting to reveal the hierarchal structure of gene reg-
ulatory networks, a full grasp of their complexity can only
be achieved when combined with intricate knowledge of
the underlying CREs to which these transcription factors
bind. The latter analysis has until recent years been lag-
ging behind.
Characteristics of cis-Regulatory DNA
CREs are short stretches of noncoding DNA, typically 200–
500 base pairs in length, that contain sequence motifs that are
recognized and bound by transcription factors (Fig. 1a) [27,
28]. The spacing, location and sequence content of these bind-
ing motifs can be either very relaxed or tightly determined
depending on which enhancer is assayed [29]. The number
of potential binding motifs within the genome for a given
transcription factor typically outpaces the number of actual
binding events by an order of magnitude [30]. This is primar-
ily explained by the combinatory nature of transcription factor
binding [30–32]. Typically, a hierarchical sequence of binding
events will start with the docking of so-called pioneer factors
that promote the accessibility of DNA to other proteins
[32–34]. This will stabilize a core complex that in turn recruits
other, more ubiquitously expressed, cofactors through protein-
protein interactions [35]. These cofactors can further modify
the local chromatin environment by adding defined epigenetic
modifications to histone tails, thus creating additional docking
sites for proteins and further altering local chromatin state
[36]. Alternatively, they may directly influence transcription
initiation at the core promoter.
The combined activity of different transcription factors
bound to a single element ultimately determines its regu-
latory capacity as being an activator (enhancer) or repres-
sor (silencer) of gene expression. CREs are considered
part of the promoter when located next to a gene’s tran-
scriptional start site onto which the RNA polymerase II
transcription initiation complex is assembled. However,
they can also be situated at large genomic distances (up
to 1 million base pairs [9]) and interact with the promoter
of their target gene through a process called chromatin
looping [37, 38]. Several factors such as CCCTC-
binding factor (CTCF), mediator and cohesin are involved
in the establishment of these long-range interactions
[39–41]. The genomic architecture within a cell’s nucleus
is further shaped by CTCF boundaries, called insulators,
into neighbourhoods in which genes and their CREs are
isolated (Fig. 1a) [41–43]. Target gene regulation is often
restricted to these domains and dependent on the com-
bined activity of CREs [40]. Genes can also be regulated
by multiple enhancers in a modular fashion meaning that
separate enhancers support gene expression in a particular
anatomical structure or cell type (Fig. 1a) [29, 32]. For
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instance, different neural enhancers independently regu-
late the expression of proopiomelanocortin across several
neuroanatomical regions [44]. Therefore, sets of transcrip-
tion factors operate through a number of CREs to orches-
trate the activation and repression of genes into well-
defined transcriptional programs.
Genome-Wide Annotation of CREs
Early discovery of CREs relied on the careful analysis of
a handful of single gene regions [45]. One of the most
well-studied examples is the beta-globin locus [46].
Similar efforts have led to the identification of regulatory
DNA that acts on the Pax6 gene in the lens. Later, it
became clear that Pax6 is under the control of multiple
enhancers to strictly regulate its expression in the eye,
brain and pancreas [47]. This underscored the function
of enhancers as modular regulators of gene expression in
a cell type-specific manner.
Based on the fact that gene function is typically conserved
across species, the assumption that gene regulation would be
equally conserved led to the identification of several thou-
sands of predicted enhancer sequences across species using
comparative genomics [48, 49]. Typically, half of these highly
conserved elements contained measurable enhancer activity
when tested in transgenic animals using reporter assays and
a significant portion supported expression in the developing
nervous system [49, 50]. However, several enhancers that
were found by analysing specific genes of interest displayed
little evidence of sequence conservation, with some showing
no sequence conservation despite being functionally con-
served [51, 52]. This raised the question on how much regu-
latory information was still missing.
The realization that cis-regulatory DNA contains specific
epigenetic footprints [53, 54], combined with the emergence
of large-scale sequencing techniques to measure them
genome-wide [53], has significantly propelled our under-
standing of the regulatory networks that dictate gene expres-
sion. For instance, CREs typically reside in open chromatin
Fig. 1 Cis-regulatory elements in gene expression and disease. a. The
genome is subdivided into chromatin neighbourhoods (upper panel).
Within domains, delineated by CTCF (green) and typically analyzed by
chromatin conformation capture techniques (hypothetical Hi-C result
shown), enhancers drive target gene expression through long-range
interactions with the promoter of their target gene (two examples shown
below the domains). Enhancers often regulate genes in a tissue-specific
manner as depicted here for the brain (blue) and liver (red). Functional
CREs comprise stretches of binding motifs that are bound by
transcription factors to ultimately determine CRE activity (bottom). b.
The combination of enhancer identification and GWAS studies has
revealed that many single nucleotide polymorphisms (yellow) lie within
cis-regulatory DNA (blue, H3K27ac in the brain; red, H3K27ac in the
liver). Variation within CREs can contribute to disease susceptibility and
aid in the identification of relevant cell types
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and are generally characterized by low nucleosome density in
combination with defined histone variants or histone modifi-
cations [36]. The accessibility of CREs can be exploited to
chart their location at a genome-wide level using a variety of
large-scale assays [55–57]. While most of the identified re-
gions are likely enhancers, open chromatin also contains in-
sulators bound by CTCF [58], repressors such as regions oc-
cupied by REST (RE1 silencing transcription factor) [59] and
potential other regulatory elements [60].
Different types of CREs are associated with distinct histone
signatures and transcription factors [36, 61], the location of
which can be measured by chromatin immunoprecipitation
(ChIP) followed by sequencing. Promoters are mainly marked
by histone 3 lysine 4 mono-methylation (H3K4me1) and
H3K4me3, while H3K4me1 in the absence of H3K4me3 se-
lectively associates with distal regulatory regions [61].
H3K4me1 may function to protect genomic regions from re-
pressors that bind unmodified H3K4 [62, 63] or alternatively
as a docking site for factors that enhance the regulatory po-
tential of the region by altering its accessibility [64]. This
signature is found at enhancers that are active, poised or re-
pressed and remains long after activity has seized [61, 65–67].
The presence of histone 3 lysine 27 acetylation (H3K27ac) is
indicative of active promoters as well as enhancers [6, 65,
67–69]. The acetyltransferases p300 and CREB binding pro-
tein (CBP) that deposit H3K27ac are similarly used to identify
enhancers [70]. Acetylated lysines direct regulatory activity
by serving as docking sites for bromodomain containing co-
factors [71]. However, they also influence chromatin compac-
tion by attenuating histone-DNA interactions through the neu-
tralization of electrostatic interactions [72]. Acetylation-based
enhancer predictions are confirmed in reporter assays in
∼70 % of the cases presuming that a substantial fraction of
the enhancer sequence is assayed [2, 23, 32, 35]. Furthermore,
the discovery rate of enhancers using acetylated lysines is also
relatively high [68]. Other assays to assess enhancer activity
have been explored and were shown to be indicative of tissue-
specific activity as well [73–75]. However, as CRE identifica-
tion through the use of histone marks is relatively easy and
robust, it currently remains the most frequently used method.
Emerging Concepts from Large-Scale Identification
of cis-Regulatory DNA
The epigenomic analysis of regulatory networks has substan-
tially enhanced our understanding of how CREs operate, how
these elements evolved across evolutionary time and accord-
ing to which rules target genes are specified and controlled.
For instance, the majority of distal regulatory elements were
found to function as enhancers (over 400,000 predicted), often
in a temporal and tissue-specific manner [1, 2, 54, 70]. In
contrast, promoters, insulators and the overall topological
structure of the genome were mostly found conserved
between cell types [54, 76]. Similar observations were done
over evolutionary time. While enhancer activity was shown to
be poorly conserved across species, promoters and chromatin
architecture were overall similar [77–81]. The fact that en-
hancers are highly tissue-specific as well as the fact that mul-
tiple enhancers can act together on a single gene in a redun-
dant fashion, partially explains this lack of conservation [82,
83]. Furthermore, redundancy in recognition motifs allows
enhancers to remain functionally conserved despite a lack of
sequence similarity [51, 52, 84–86].
Different types of promoter and enhancer elements were
discovered based on their activity. Enhancers can be active
(bound by H3K27ac), while they can also exist in a poised
state ready to be activated [65, 67]. A poised state is part of the
transcriptional program that specifies cell state and gives the
cell a set of transcriptional options to deploy rapidly in re-
sponse to environmental cues. For instance, neurons are able
to quickly integrate external stimuli and translate this into
gene expression changes that can be either short or persist
for longer periods. This signalling network, which is impor-
tant during brain development to stabilize synapses, is also
involved in synaptic plasticity and thus learning, cognition
and memory [87]. Recent data in mouse cortical neurons,
demonstrated that activity-dependent transcriptional changes
are at least partially established through rapid epigenetic alter-
ations in a pre-programmed poised enhancer network by the
early response factor FOS [74, 88••].
While these principles represent some of the emerging
concepts coming from large- scale CRE identification, one
of the most important insights gained from these analyses
is that much of the unexplained heritability of disease
phenotypes might be located in deregulated noncoding
regulatory regions [12].
Misregulation of Enhancers in Disease
The importance of correct gene expression control is
underscored by the misregulation or mutation of transcription
factors in numerous diseases [4]. For instance, ASCL1 muta-
tions can give rise to Ondine’s curse, a severe neurological
disorder that leads to fatal sleep apnoea [89]. However, the
effects of mutations within transcription factors are often
pleiotropic and thus affect multiple cell types resulting in se-
vere developmental defects that are typically incompatible
with life. Instead, many disorders are characterized by more
subtle tissue-specific defects. For example, mutations in the
coding sequence for sonic hedgehog (SSH) lead to early ter-
mination of embryonic development while a mutation within
an enhancer that regulates SSH expression in the limb bud
specifically causes preaxial polydactyly [9]. While this phe-
notype arises from faulty expression of SSH, misregulation
is restricted to the developing limb and therefore irrelevant
in other tissues.
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Early studies targeting specific genomic loci by extensive
long-range mapping have established a handful of enhancers
as causative in very specific disorders such as the beta-globin
enhancers in Thalassemia’s [90, 91] and a RET enhancer in
Hirschsprung disease [92, 93]. After these observations, addi-
tional enhancer mutations were found in a variety of disorders
including Pierre Robin syndrome [10], pancreatic agenesis
[94] and congenital heart disease [95]. The latter underscored
the modularity of enhancers as mutations in TBX5 (T-box 5)
result in congenital heart defects and limb malformations
while mutations in single enhancers could decouple these
phenotypes.
In addition, several different modes of enhancer deregula-
tion were uncovered. In acute lymphoid leukaemia, aberrant
transcriptional regulation was found to result from point mu-
tations that created a new enhancer in front of the TAL
(Transcription activator-like) oncogene [96]. Enhancer driven
oncogene activation was also shown to occur as a result of
enhancer translocations including the classic example of
Burkitt lymphoma in which the MYC oncogene falls under
the control of an immunoglobulin enhancer after a t(8;14)
chromosomal translocation [97]. More recently, it was dem-
onstrated that oncogene activation can occur after disruption
of insulated chromatin neighbourhoods [98, 99]. As a result,
expression of proto-oncogenes was increased through newly
established long-range interactions. Finally, the epigenomic
deregulation of enhancers by loss of DNA methylation was
shown to be widespread in tumours [100]. These results dem-
onstrate that diverse modes of enhancer misregulation can
underlie a host of diseases and can explain the tissue-
specific manifestation of such disorders.
Enhancers as a Source for Common Variation in Disease
Susceptibility
With more than 400,000 potential noncoding regulatory ele-
ments identified in the human genome, the mutational space
for disease-causing events has increased substantially. The
inability to explain disease heritability by gene mutations
alone as well as the presence of more than 85 % of disease-
associated variants in noncoding DNA [101] have strength-
ened the notion that much of the genetic variation that is rel-
evant to disease lies within regulatory DNA (Fig. 1b). This has
been supported by earlier extensive investigation of the RET
gene locus for which a common variant within aRETenhancer
was found to increase Hirschsprung disease susceptibility
[102, 103]. Nevertheless, linking the disease-associated vari-
ant to specific regulatory elements often remained challeng-
ing. For instance, in depth analysis of a risk haplotype in the 5′
region of SORL1 (sortilin-related receptor L) provided impor-
tant new insight into the pathogenesis of Alzheimer’s disease
while the exact polymorphism behind this effect remained
elusive [104].
Based on these observations, the integration of genome-
wide association studies with datasets of annotated enhancer
elements has rapidly led to the discovery of potential disease-
associated variants in predicted enhancer elements (Fig. 1b)
[105–110]. This revealed that common disease variants pref-
erentially occurred at enhancers in cell types known to be
affected by the disease and therefore yielded a trove of candi-
dates for further study. For example, while common variants
that alter susceptibility to behavioural disorders preferentially
occurred in foetal brain CREs [106], common variants asso-
ciated with increased Parkinson’s disease (PD) susceptibility
were found preferentially in CREs of the adult human brain
(Fig. 1b) [111•]. In agreement with this, a number of neural
transcription factor binding sites (e.g. Pax6 and Otx1) were
disproportionally affected by variants associated with neuro-
psychiatric diseases and traits [106]. Several surprising obser-
vations were also made such as an unexpected link between
B-cells and multiple sclerosis [106]. This suggested that spe-
cific cell types that are affected in disease could be deducted
from the integration of cell type-specific enhancers and
genome-wide association (GWAS) data (Fig. 1b). Similarly,
in a more recent study, common variation in Alzheimer’s dis-
ease was linked to the immune system suggesting that much
of the regulatory variation underlying this disease may not be
intrinsic to neurons [112]. This underscores the relevance of
integrating the two data types to uncover new cell types that
are involved in disease susceptibility but also to prioritize the
regulatory elements that are likely affected by genomic varia-
tion. Furthermore, it solidifies the notion that intra-individual
genetic variation, which is most pronounced at regulatory
DNA [113, 114], plays an integral role in determining disease
susceptibility [108–110].
Parkinson’s Disease-Associated Variation Within Human
Brain Enhancers
While genomic variation within CREs is likely to have func-
tional consequences, the link between potentially relevant en-
hancer variants and disease has to be experimentally verified.
This has been done for a handful of disorders such as the FTO
(fat mass and obesity-associated) locus in obesity [11], LMO1
(LIM domain only 1) in neuroblastoma predisposition [115]
and BCL11A (B-cell lymphoma/leukaemia 11A) in sickle cell
anaemia [116•]. However, proper validation is difficult, espe-
cially for complex diseases such as neurodegenerative and
neuropsychiatric disorders in which the combined activity of
several regulatory elements on multiple genes may underlie
pathophysiology. Furthermore, given the moderate effect size
of common variations on disease susceptibility, the effect size
on gene expression may also be modest.
We have previously linked several genetic variants associ-
ated with altered PD susceptibility to enhancers of the adult
brain [111•]. These included CREs in important PARK loci
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such as the PARK16, PARK17 and the PARK8 loci, contain-
ing LRRK2 (Leucine-rich repeat kinase 2), a gene that is mu-
tated in autosomal dominant PD [117]. Similarly, we identi-
fied an intronic enhancer in the SNCA (α-synuclein) gene that
contained two genomic variants rs356168 and rs3756054
[111•] that were in perfect linkage with earlier described PD
risk alleles rs2736990 and rs11931074. These were initially
discovered in cohorts of European and of Asian descent, re-
spectively [118, 119]. This suggested that the different com-
mon variants in two populations converged at one enhancer
element. In support of a role for enhancer variation, we found
that both of these linked variants altered transcription factor
binding sites in the predicted enhancer. Furthermore, the reg-
ulatory region acted as an enhancer in transgenic mouse as-
says, phenocopying the expression of SNCA in E11 mouse
embryos. Finally, the enhancer was shown to directly target
the SNCA promoter in chromosome conformation capture ex-
periments in human brain tissue [111•]. These data firmly
established the newly identified CRE as a bona fide SNCA
enhancer.
As enhancers are mostly cell type- and context-specif-
ic, a correct model system and environment needs to be
established to explore the functional consequences of en-
hancer alteration. This can be particularly difficult for the
nervous system [120]. In addition, the effect size of en-
hancer variation is likely modest, given the fact that a
50 % increase in SNCA expression will cause PD [121].
A recent study dealt with all of these issues by employing
an elegant experimental set up to analyse the influence of
genetic variation within the intronic SNCA enhancer using
allele-specific SNCA expression analysis in embryonic
stem cell-derived neurons [122••]. Slight, but consistent
increased expression of SNCA was observed for the
Parkinson’s variant of rs356168 but not for variant
rs3756054. This suggests that the latter SNP may not
contribute to disease susceptibility and that other variants
with lower linkage may still have to be explored.
Nevertheless, these data did confirm our previously pro-
posed link between the rs356168 enhancer variant and PD
susceptibility. This underscores the importance of rigor-
ous validation of enhancer variants within CREs and
stands as a testimony for the huge task ahead.
Conclusion
CREs play a pivotal role in the proper establishment of
the gene expression programs that determine cell state.
Following a decade of epigenomic exploration to chart
CREs in the human genome, we are now starting to un-
ravel some of the regulatory networks that contribute to a
host of brain disorders as well as to individual variation in
disease susceptibility. Since the start of the ENCODE
project, to the more recent report of 111 epigenomes by
the Roadmap Epigenetics Consortium, both consortia
have added hundreds of datasets of different epigenetic
footprints in a host of human tissues including 8 adult
and 2 foetal brain samples [6]. However, to capture the
full complexity of the brain many more anatomical re-
gions still need to be explored. Our analysis of 87 ana-
tomically distinct regions in the human brain was a con-
firmation of this, as many specialized structures within the
brain, that were not included in other analyses, contribut-
ed significantly to the total repertoire of predicted CREs
in the human brain [111•]. Follow-up analyses to identify
regulatory changes that could be relevant to brain diseases
are underway with consortia such as PsychENCODE fo-
cussing on neuropsychiatric diseases including autism and
schizophrenia [123]. These studies will have to be bal-
anced between the number of epigenetic footprints
analysed, the number of patients included and the number
of anatomical regions required. Furthermore, new (single
cell) methods will have to be optimized to tackle the in-
vestigation of rare cell types within brain tissue samples.
While many potential links between neurodegenerative
disease and regulatory changes have already been revealed,
extensive validation experiments are required to confirm these
in detail. This is challenging because of the modest effect size
of sequence variation on enhancer function and the potential
involvement of multiple genes as well as the requirement of
relevant model systems in which activity can be properly mea-
sured. CRISPR-Cas9 mediated engineering of human embry-
onic stem cells will prove a powerful tool to analyse the effect
of enhancers on their cognate target gene [124], especially
since these cells can be used to generate a host of different
cell types in the brain [120]. However, as multiple cell types
can be involved in complex diseases, the implementation of
more complex culture systems such as organoid cultures, that
mimic cortical development, may be of use [125, 126].
Finally, the current focus on common variation will have to
be complemented with research on structural and rare variants,
as those are also likely to affect enhancer activity [105]. Since
transcription factor binding sites are often degenerate,
allowing multiple variations to activate or inactivate enhancer
elements, disease-causing mutations will likely be rare.
Therefore, genetic as well as epigenetic screens to reveal rare
variants and to assay their consequences on enhancer activity
will need to be explored.
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